These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32331368)

  • 1. Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death.
    Kopecka J; Godel M; Dei S; Giampietro R; Belisario DC; Akman M; Contino M; Teodori E; Riganti C
    Cells; 2020 Apr; 9(4):. PubMed ID: 32331368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells.
    Kopecka J; Campia I; Brusa D; Doublier S; Matera L; Ghigo D; Bosia A; Riganti C
    J Cell Mol Med; 2011 Jul; 15(7):1492-504. PubMed ID: 20716130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
    Wanek T; Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Sauberer M; Mairinger S; Strommer S; Wacheck V; Löscher W; Erker T; Müller M; Langer O
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):149-59. PubMed ID: 21983837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein.
    Abd-Ellatef GEF; Gazzano E; El-Desoky AH; Hamed AR; Kopecka J; Belisario DC; Costamagna C; S Marie MA; Fahmy SR; Abdel-Hamid AZ; Riganti C
    Pharmacol Res; 2022 Jan; 175():105975. PubMed ID: 34785319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
    Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.
    Kopecka J; Rankin GM; Salaroglio IC; Poulsen SA; Riganti C
    Oncotarget; 2016 Dec; 7(52):85861-85875. PubMed ID: 27811376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance.
    Huang IP; Sun SP; Cheng SH; Lee CH; Wu CY; Yang CS; Lo LW; Lai YK
    Mol Cancer Ther; 2011 May; 10(5):761-9. PubMed ID: 21411714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats.
    Müllauer J; Karch R; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Mairinger S; Müller M; Löscher W; Langer O; Kuntner C
    Nucl Med Biol; 2013 Aug; 40(6):755-63. PubMed ID: 23774004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter.
    Seebacher NA; Lane DJ; Jansson PJ; Richardson DR
    J Biol Chem; 2016 Feb; 291(8):3796-820. PubMed ID: 26601947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
    Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
    Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC.
    Seebacher NA; Richardson DR; Jansson PJ
    Cell Death Dis; 2016 Dec; 7(12):e2510. PubMed ID: 27906178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells.
    Riganti C; Castella B; Kopecka J; Campia I; Coscia M; Pescarmona G; Bosia A; Ghigo D; Massaia M
    PLoS One; 2013; 8(4):e60975. PubMed ID: 23593363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).
    Jansson PJ; Yamagishi T; Arvind A; Seebacher N; Gutierrez E; Stacy A; Maleki S; Sharp D; Sahni S; Richardson DR
    J Biol Chem; 2015 Apr; 290(15):9588-603. PubMed ID: 25720491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular Doppler Spectroscopy detects altered drug response in SKOV3 tumor spheroids with silenced or inhibited P-glycoprotein.
    Narayanan G; Merrill D; An R; Nolte DD; Turek JJ
    Biochem Biophys Res Commun; 2019 Jul; 514(4):1154-1159. PubMed ID: 31103263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
    Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
    Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner.
    Yang PM; Hsieh YY; Du JL; Yen SC; Hung CF
    Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
    Zahra R; Furqan M; Ullah R; Mithani A; Saleem RSZ; Faisal A
    PLoS One; 2020; 15(6):e0233993. PubMed ID: 32484843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.
    Leontieva OV; Preobrazhenskaya MN; Bernacki RJ
    Invest New Drugs; 2002 Feb; 20(1):35-48. PubMed ID: 12003193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
    Fox E; Widemann BC; Pastakia D; Chen CC; Yang SX; Cole D; Balis FM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1273-83. PubMed ID: 26486517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells.
    Jafari S; Lavasanifar A; Hejazi MS; Maleki-Dizaji N; Mesgari M; Molavi O
    Daru; 2020 Jun; 28(1):159-169. PubMed ID: 31942696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.